Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease
Conclusions
Our study confirms that FGF23 is an important cardiovascular risk factor. Two measurements of FGF23 have no added value over a single value to predict the cardiovascular outcome. This study demonstrates that, under routine clinical practice, the variability of FGF23 in 2 years' time is small. Concomitantly, this study showed no benefit of consecutive FGF23 testing for estimating the risk of a clinical event in an individual patient.
Source: Nephrology Dialysis Transplantation - Category: Urology & Nephrology Authors: Bouma-de Krijger, A., Bots, M. L., Vervloet, M. G., Blankestijn, P. J., ter Wee, P. W., van Zuilen, A. D., Wetzels, J. F. Tags: Chronic Kidney Disease Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Congestive Heart Failure | Dialysis | Heart | Heart Attack | Heart Failure | Heart Transplant | Kidney Transplant | Kidney Transplantation | Stroke | Study | Transplants | Urology & Nephrology